Compare DexCom, Inc. (DXCM) vs Vanguard Emerging Markets Stock Index Fund ETF (VWO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs Vanguard Emerging Markets Stock Index Fund ETF — how do they compare? DexCom, Inc. trades at $83.73 (market cap $31.86B), while Vanguard Emerging Markets Stock Index Fund ETF trades at $59.65 (market cap $168.50B). The key difference: Vanguard Emerging Markets Stock Index Fund ETF is far larger — about 5.3× DexCom, Inc.'s market cap, and Vanguard Emerging Markets Stock Index Fund ETF is more actively traded (9,650,999 versus 3,607,070). Which is the better fit depends on your goals — on Pluang, investors hold DexCom, Inc. for 62 Days and Vanguard Emerging Markets Stock Index Fund ETF for 134 Days on average.
| DXCM | VWO | |
|---|---|---|
Market Cap | $31.86B | $168.50B |
Volume | 3,607,070 | 9,650,999 |
Sector | Health | — |
52-Week High | $92.34 | $61.44 |
52-Week Low | $54.84 | $52.42 |
Typical Hold Time | 62 Days | 134 Days |
Enterprise Value | $31.32B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DexCom (DXCM) trades at $84.03, down 0.32% on the day, with strong fundamental performance including three consecutive quarterly EPS beats and robust 20.12% net income margin. The stock shows bearish technical signals with price near pivot point support at $84, while analyst consensus remains overwhelmingly positive with 81% buy ratings and $95.07 price target representing 13% upside potential. Recent news highlights expansion opportunities in Type 2 diabetes care and executive promotions.
DXCM presents a compelling growth story with expanding profit margins and consistent earnings outperformance, though technical weakness and premium valuation create near-term headwinds. The company's leadership in continuous glucose monitoring and Type 2 diabetes market expansion provide long-term catalysts, while competition and reimbursement risks require monitoring.
VWO trades at $59.77, down 0.13% on the day, with a bearish technical signal from moving averages and key indicators like ADX signaling selling pressure. Recent news highlights a divergence in performance, with AI-driven strength in Taiwan holdings like TSMC offset by economic weakness in China. The ETF's focus on over 6,000 emerging-market stocks provides diversification but faces concentration risks.
The outlook is cautious due to mixed technicals and regional economic headwinds, particularly in China. Opportunities exist from AI infrastructure growth, but risks include currency volatility and reliance on a few key markets. Investors should weigh the ETF's low expense ratio against emerging-market volatility and slowing growth in major constituents.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About Vanguard Emerging Markets Stock Index Fund ETF
The fund employs an indexing investment approach designed to track the performance of the FTSE Emerging Markets All Cap China A Inclusion Index. It invests by sampling the index, meaning that it holds a broadly diversified collection of securities that, in the aggregate, approximates the index in terms of key characteristics.
Read more on VWO →
